Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Other Working Capital Changes (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Other Working Capital Changes for 9 consecutive years, with -$11.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Working Capital Changes fell 372.58% to -$11.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.6 million, a 14.78% increase, with the full-year FY2025 number at -$7.6 million, up 14.78% from a year prior.
  • Other Working Capital Changes was -$11.5 million for Q4 2025 at Akebia Therapeutics, down from $7.4 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $15.2 million in Q3 2021 to a low of -$12.5 million in Q2 2021.
  • A 5-year average of -$972350.0 and a median of -$1.9 million in 2024 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: soared 9219.02% in 2021, then plummeted 884.03% in 2022.
  • Akebia Therapeutics' Other Working Capital Changes stood at -$1.3 million in 2021, then crashed by 153.64% to -$3.2 million in 2022, then skyrocketed by 207.72% to $3.5 million in 2023, then crashed by 169.5% to -$2.4 million in 2024, then tumbled by 372.58% to -$11.5 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Other Working Capital Changes are -$11.5 million (Q4 2025), $7.4 million (Q3 2025), and -$2.2 million (Q2 2025).